# CORLANOR — FDA application NDA206143

Informational only - not investment advice.

Application NDA206143 · type NDA · FDA status: approved · original approval 2015-04-15

Listed sponsor: AMGEN INC · [AMGN company profile](/company/AMGN/) · exact_unique

Sponsor as listed in Drugs@FDA at retrieval (2026-08-07); FDA sponsor listings can lag ownership transfers.

## FDA application facts

| Product | FDA-listed trade name | Active ingredient | Dosage form | Route | Strength | Marketing status | TE code | RLD |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 001 | CORLANOR | IVABRADINE HYDROCHLORIDE | TABLET | ORAL | EQ 5MG BASE | Discontinued | not listed | Yes |
| 002 | CORLANOR | IVABRADINE HYDROCHLORIDE | TABLET | ORAL | EQ 7.5MG BASE | Discontinued | not listed | Yes |

## Orange Book patent and exclusivity listings

- Patent 7361649, product 001; listed patent expiry date: 2026-02-22.
- Patent 7361649, product 002; listed patent expiry date: 2026-02-22.
- Patent 7361650, product 001; listed patent expiry date: 2026-02-22.
- Patent 7361650, product 002; listed patent expiry date: 2026-02-22.
- Patent 7879842, product 001; listed patent expiry date: 2026-02-22.
- Patent 7879842, product 002; listed patent expiry date: 2026-02-22.
- Patent 7361649, product 001; listed patent expiry date: 2026-08-22.
- Patent 7361649, product 002; listed patent expiry date: 2026-08-22.
- Patent 7361650, product 001; listed patent expiry date: 2026-08-22.
- Patent 7361650, product 002; listed patent expiry date: 2026-08-22.
- Patent 7879842, product 001; listed patent expiry date: 2026-08-22.
- Patent 7879842, product 002; listed patent expiry date: 2026-08-22.
- Patent 7867996, product 001; listed patent expiry date: 2026-12-12.
- Patent 7867996, product 002; listed patent expiry date: 2026-12-12.
- Patent 7867996, product 001; listed patent expiry date: 2027-06-12.
- Patent 7867996, product 002; listed patent expiry date: 2027-06-12.

Patent and exclusivity dates are regulatory listings from the FDA Orange Book; no relationship to revenue or future sales is stated or implied.

## Compound cross-links

- IVABRADINE HYDROCHLORIDE · UNII TP19837BZK · [lmmol compound HLUKNZUABFFNQS-ZMBIFBSDSA-N](https://lmmol.com/compound/HLUKNZUABFFNQS-ZMBIFBSDSA-N)

Ingredient–compound links use FDA openFDA/GSRS identifiers and an exact lmmol InChIKey join. Ingredient names cannot create a link.

## Related pages

- [Sponsor company](/company/AMGN/)
- [FDA-approved application index](/drug/)
- [Large-cap biopharma](/compare/pharma/)

Sources: https://www.fda.gov/drugs/drug-approvals-and-databases/drugsfda-data-files · https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files · https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA206143. FDA data retrieved 2026-08-07.

Regulatory listing data as published by FDA; not medical or investment advice.